Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis
Karthik Ramasamy(Oxford University Hospitals NHS Trust), Pieter Sonneveld(Erasmus MC Cancer Institute), Katja Weisel(Universität Hamburg), Shona Collins(National and Kapodistrian University of Athens), Niels W.C.J. van de Donk(Oncode Institute), Meletios Α. Dimopoulos(Korea University), Frederik Lersch(Bristol-Myers Squibb (Switzerland)), Barbara Gamberi(University of Modena and Reggio Emilia), Matthew Streetly(King's College - North Carolina), Frank Bridoux(Université de Poitiers), Elisabeth Kueenburg(National and Kapodistrian University of Athens), Pamela Bacon(National and Kapodistrian University of Athens), Barbara Rosettani(National and Kapodistrian University of Athens)
Cited by 6
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k